<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20130610013612N11</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-09-23</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Effects of Fumaria Parviflora  on diabetic patients</public_title>
      <acronym></acronym>
      <scientific_title>The effect of Fumaria Parviflora hydro-alcoholic extract on lipid profile, blood glucose indices, inflammatory factors, oxidative stress indices, and liver enzymes in patients with type 2 diabetes under a low-calorie diet</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>66</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58544</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: In the current study, we will apply block randomization, one type of restricted randomization. Blocking is usually used to make a balance in the number of assigned samples to each studies group. This characteristic helps researchers in assigning an equal number of samples to each group, in cases that middle analyses are needed during the sampling process. The size of all the blocks is equal and in this two-group experiment, we will have 6 blocks (including 3 participants in the intervention group and 3 participants in the control group). Randomization tool also uses random allocation software that these random sequence generation software in addition to simple randomization are able to generate a random sequence by blocking method. For concealment, we use concealment allocation, which is the method used to execute a random sequence on study participants, so that the assigned group is not known before the individual is assigned. Using sealed opaque envelopes with random sequences (envelopes opaque, sealed, numbered sequentially) in which in this method each of the random sequences created is recorded on a card, and the cards inside the envelopes are placed in order. In order to maintain a random sequence, the envelopes are numbered in the same way on the outer surface. Finally, the lids of the letter envelopes are glued and placed in a box, respectively. At the beginning of the registration of participants, based on the order of entry of eligible participants into the study, one of the envelopes is opened in order and the assigned group of the participant is revealed, Blinding description: To reduce the bias or bias related to the intervention and the evaluation of outcomes, the double-blind method is used. In this way, the outcome can be measured objectively. In this method, the trial is planned in such a way that the participant and the researcher do not realize which of the two control or test groups they belong to.</study_design>
      <phase>3</phase>
      <hc_freetext>Type 2 diabetic patients.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: receives 550 mg daily of hydro-alcoholic extract of fumaria Parviflora for 2 months. Intervention 2: Control group: receive 550 mg daily of placebo consisting of cornstarch for 2 months.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Farzad Najafipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Endocrinology, Imam Reza Hospital, Tabriz University of Medical Sciences, Golgasht Street, Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614756</zip>
        <telephone>+98 41 3335 7850</telephone>
        <email>Farzadnajafipour@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Frazad Najafipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Reza Hospital, Endocrinology and Metabolism Department</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614766</zip>
        <telephone>+98 914 107 8522</telephone>
        <email>najafipourf@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients who agree to participate in the study
Women aged 20 to 50 years (non-menopausal) and men 20 to 65 years
BMI range between 25 and 40 kg /m2
;  Having type 2 diabetes for at least 6 months while taking blood sugar-lowering drugs (metformin and thiazolidine )</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Reluctance to participate in the study
Insulin injection
Use any nutritional supplements such as omega-3 supplements or supplements that have anti-inflammatory and antioxidant properties in the past 3 months or during the study
Liver and kidney failure and thyroid diseases
Smoking and alcohol consumption
Patients using NSAIDs, corticosteroids (prednisone, prednisolone, and hydrocortisone), thiazide (furosemide and hydrochlorothiazide), and second-generation antipsychotics (olanzapine and clozapine).
Pregnancy and desire to conceive during the study
Intestinal and gastrointestinal diseases and eating disorders</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E08</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diabetes mellitus due to underlying condition</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: receives 550 mg daily of hydro-alcoholic extract of fumaria Parviflora for 2 months</i_keyword>
      <i_keyword>Control group: receive 550 mg daily of placebo consisting of cornstarch for 2 months</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Total cholesterol. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Blood Test.</prim_outcome>
      <prim_outcome>Triglyceride. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Blood Test.</prim_outcome>
      <prim_outcome>High-density lipoprotein. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Blood Test.</prim_outcome>
      <prim_outcome>Low-density lipoprotein. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Blood Test.</prim_outcome>
      <prim_outcome>Atherogenic index of plasma. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Blood Test.</prim_outcome>
      <prim_outcome>Tumour Necrosis Factor alpha. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Blood Test.</prim_outcome>
      <prim_outcome>Interleukin 6. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Blood Test.</prim_outcome>
      <prim_outcome>Intercellular Adhesion Molecule 1‎. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Blood Test.</prim_outcome>
      <prim_outcome>Total antioxidant capacity. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Blood tests.</prim_outcome>
      <prim_outcome>Malondialdehyde. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Blood tests.</prim_outcome>
      <prim_outcome>Glutathione peroxidase. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Blood tests.</prim_outcome>
      <prim_outcome>Superoxide dismutase. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Blood tests.</prim_outcome>
      <prim_outcome>Catalase. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Blood tests.</prim_outcome>
      <prim_outcome>MCP-1gene expression. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Measurement of gene expression by RT-PCR method.</prim_outcome>
      <prim_outcome>Nf-kB gene expression. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Measurement of gene expression by RT-PCR method.</prim_outcome>
      <prim_outcome>BAX gene expression. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Measurement of gene expression by RT-PCR method.</prim_outcome>
      <prim_outcome>Nrf-2 gene expression. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Measurement of gene expression by RT-PCR method.</prim_outcome>
      <prim_outcome>BCL-2 gene expression. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Measurement of gene expression by RT-PCR method.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Anthropometric indecs. Timepoint: Baseline and 2 months after the intervention. Method of measurement: Body composition measuring device.</sec_outcome>
      <sec_outcome>Antropometric indices (Weight, Height, BMI, Waist circumference, Hip circumference, Waist to Hip Ratio). Timepoint: Baseline and 2 months after the intervention. Method of measurement: Physical exam.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-07-26</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Tabriz University of Medical Sciences, Daneshgah Sq. Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
